Industry Perspectives

Eppendorf Safe-Lock Tubes BioBased are made from 100 percent renewable biobased feedstock of second generation

AI could transform clinical trials, but its impact depends on overcoming deep-rooted challenges in data sharing, trust, regulation, and collaboration.

Breakthrough data validates capabilities of GlueSEEKER platform to identify novel induced protein-protein interactions and expand druggable space

Data-led engineering and platform strategies are transforming T cell engagers into scalable, clinically viable cancer therapies.

A domain-specific AI platform enables scientists to generate and test hypotheses faster, helping pharma teams reduce target prioritization timelines from weeks to days.

Synthetic control arms are emerging as a valuable solution for clinical trials where using traditional placebo groups is difficult, unethical, or impractical.

Expanded high-value end-to-end solution positions business for rapid growth in multi-billion dollar functional GI market

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies

Efforts to move beyond long-term steroid use are accelerating, with growing awareness of steroid toxicity, new tools to guide tapering, and emerging therapies offering safer alternatives.

Intuitive software supports 24 hours of continuous runtime and easy analysis of complex high-throughput datasets

Multiomic approaches are advancing cancer research by delivering deeper insights and enabling more precise diagnostics and therapies.

A breakthrough from AI|ffinity and NexMR was achieved with a 100-fold affinity improvement in the initial round of drug discovery using ultrafast NMR screening and AI-driven lead generation against intrinsically disordered protein targets.